Search Results
53 Results Found for “Artificial intelligence”
Cardiovascular diseases (CVDs) are the leading cause of morbidity and mortality worldwide.1 High systolic blood pressure (SBP) remains one of the top risk factors for CVD burden globally.2 Despite being a modifiable risk factor, hypertension (HTN) remains largely undiagnosed and ...
Large language models, wearables and mobile health technologies are increasingly being explored across cardiovascular research and clinical care. At ESC Congress 2026, Dr Jazmin Aguado-Sierra discussed where these tools could add value, and where questions around reliability remain.
Dr Jazmin Aguado-Sierra discusses how computational models and digital twins are helping researchers understand different heart failure phenotypes, and how artificial intelligence can accelerate analysis and support more personalized approaches.
Prof. Jens Cosedis Nielsen discusses the DANISH-CRT trial, why targeted electrical mapping did not improve outcomes, and the questions that remain around the future of cardiac resynchronization therapy.
New heart failure guidelines, practice-changing Hot Line data, artificial intelligence and new evidence in atrial fibrillation and cardiac amyloidosis are among the highlights to look out for on the opening day of ESC Congress 2026.
ESC Congress 2026 begins in Munich on August 28, bringing four days of new cardiovascular research, clinical guidance and discussion. Early data released ahead of the meeting provide a first look at some of the science to come.
Late-breaking clinical research will once again be a major focus at ESC Congress 2026, taking place in Munich, Germany, from August 28–31. This year, a record 59 trials have been selected for presentation across 12 Hot Line sessions, spanning new pharmacological approaches, diagnostic strategies, devices, imaging and digital technologies.
New clinical guidelines, late-breaking trials, artificial intelligence, and an increasing focus on cardiometabolic and precision medicine are set to shape discussions at ESC Congress 2026 in Munich.
A new international expert consensus document has updated the universal definition of heart failure, with a greater focus on earlier detection, standardized classification and individualized risk reduction.
At EHRA 2026, Professor Claudio Tondo presents his highlights on advances in ablation and device technologies, led by pulsed field ablation, showcasing a rapidly evolving landscape in the treatment of complex arrhythmias.
Professor Amir Jadidi presented results from SOLVE-AF at EHRA 2026, showing that sinus rhythm–guided substrate ablation significantly improves outcomes in persistent AF patients with atrial fibrosis and supporting a more personalized ablation strategy.
Sudden cardiac arrest (SCA) in young adults (typically defined as individuals younger than 40 years) has emerged as an important yet under-recognized public health concern. Recent estimates suggest an incidence of approximately 1–4 cases per 100,000 person-years, underscoring the clinical and epidemiological relevance ...
From breakthrough prevention strategies to pivotal late-breaking trials, ACC.26 showcased the rapidly evolving future of cardiovascular care.
At EHRA 2026, late-breaking trials across ablation, devices, and drug therapy signal major shifts in arrhythmia management, highlighting both rapid innovation and key unanswered questions. We spoke to Prof Jose Luis Merino for his highlights.
From EHRA 2026, Dr Salik Ur Rehman discusses advances in pulsed field ablation, mapping technologies, and conduction system pacing highlight a rapidly evolving landscape in electrophysiology care.
At EHRA 2026, new research presented by Professor Elaine Chew explores how music-based digital tools can enhance arrhythmia detection and enable personalized, AI-driven approaches to cardiovascular diagnosis and therapy.
At EHRA 2026, Ben Petrazzini discussed new research that shows AI can improve identification of sudden cardiac death in electronic health records, enabling more accurate large-scale studies and advancing prevention strategies.
At ACC26, William Fearon and Ajay Kirtane presented a large randomized trial, showing angiography-derived coronary physiology is noninferior to pressure wire–guided PCI, with added procedural efficiency and potential to expand physiologic assessment in routine practice.
Log into your Touch Account
Keep track of your clinical interests and newsletter subscriptions.
Sign up with an Email
Or use a .
Register now for FREE access
Already registered? Login below.
